Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024

• Autor(es): Antunes, Liliana ; Mazagatos, Clara ; Martínez‐Baz, Iván ; Naesens, Reinout ; Borg, Maria‐Louise ; Petrović, Goranka ; Fatukasi, Terra ; Jancoriene, Ligita ; Machado, Ausenda ; Oroszi, Beatrix ; Husa, Petr ; Lazar, Mihaela ; Dürrwald, Ralf ; Howard, Jennifer ; Melo, Aryse ; Pérez‐Gimeno, Gloria ; Castilla, Jesús ; Bernaert, Eva ; Džiugytė, Aušra ; Makarić, Zvjezdana Lovrić ; Fitzgerald, Margaret ; Mickienė, Auksė ; Gómez, Verónica ; Túri, Gergő ; Součková, Lenka ; Marin, Alexandru ; Tolksdorf, Kristin ; Nicolay, Nathalie ; Rose, Angela M.C. ; European Hospital Vaccine Effectiveness Group
• Data: 2024
• Identificador Persistente: http://hdl.handle.net/10400.18/10418
• Origem: Repositório Científico do Instituto Nacional de Saúde
• Assunto(s): COVID-19 XBB.1.5; Vaccine; Estados de Saúde e de Doença; Investigação em Serviços de Saúde; SARS‐CoV‐2 Hospitalisation; Vaccine Effectiveness; Europe; Infecções Respiratórias
• Tipo de Documento: Artigo científico
• Idioma: Inglês
• Contribuidor(es): Repositório Científico do Instituto Nacional de Saúde

Descrição

We conducted a multicentre test-negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14–29days and 40% at 60–105days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5months post vaccination, with VE>70% in older adults (≥65 years) up to 1month post vaccination.